CYP4F11

Summary

CYP4F11 (cytochrome P450 family 4 subfamily F member 11, HGNC:13265) is a protein-coding gene on chromosome 19p13.12, encoding Cytochrome P450 4F11 (Q9HBI6). A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins). It is a selective cancer dependency (DepMap: 10.2% of cell lines).

This gene, CYP4F11, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This gene is part of a cluster of cytochrome P450 genes on chromosome 19. Another member of this family, CYP4F2, is approximately 16 kb away. Alternatively spliced transcript variants encoding the same protein have been found for this gene.

Source: NCBI Gene 57834 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 126 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 10.2% of screened cell lines
• MANE Select transcript: NM_021187

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13265
Approved symbol	CYP4F11
Name	cytochrome P450 family 4 subfamily F member 11
Location	19p13.12
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000171903
Ensembl biotype	protein_coding
OMIM	611517
Entrez	57834

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 15 protein_coding, 1 retained_intron

ENST00000248041, ENST00000326742, ENST00000402119, ENST00000591841, ENST00000620614, ENST00000904116, ENST00000904117, ENST00000904118, ENST00000904119, ENST00000904120, ENST00000904121, ENST00000904122, ENST00000904123, ENST00000904124, ENST00000904125, ENST00000904126

RefSeq mRNA: 2 — MANE Select: NM_021187 NM_001128932, NM_021187

CCDS: CCDS12337

Canonical transcript exons

ENST00000402119 — 12 exons

Exon	Start	End
ENSE00000873399	15929457	15929601
ENSE00001623297	15927430	15927483
ENSE00001756553	15924761	15924882
ENSE00001793630	15934211	15934529
ENSE00002860181	15912377	15913909
ENSE00003469088	15923812	15924082
ENSE00003481073	15927212	15927339
ENSE00003613432	15922364	15922430
ENSE00003709110	15914305	15914387
ENSE00003710179	15914762	15914895
ENSE00003710633	15914602	15914666
ENSE00003710694	15922037	15922166

Expression profiles

Bgee: expression breadth ubiquitous, 164 present calls, max score 93.81.

FANTOM5 (CAGE): breadth broad, TPM avg 3.2228 / max 320.8098, expressed in 384 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
179782	1.2816	335
179777	0.5804	108
179776	0.5374	84
179781	0.4797	147
179779	0.1951	89
179778	0.0871	35
179780	0.0309	13
179775	0.0229	5
208717	0.0077	6

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	93.81	gold quality
liver	UBERON:0002107	90.77	gold quality
gall bladder	UBERON:0002110	85.39	gold quality
mucosa of transverse colon	UBERON:0004991	80.59	gold quality
islet of Langerhans	UBERON:0000006	79.26	gold quality
descending thoracic aorta	UBERON:0002345	78.06	gold quality
esophagus mucosa	UBERON:0002469	77.22	gold quality
lower esophagus mucosa	UBERON:0035834	73.86	gold quality
right adrenal gland cortex	UBERON:0035827	73.68	gold quality
corpus epididymis	UBERON:0004359	72.31	gold quality
thoracic aorta	UBERON:0001515	71.87	gold quality
right adrenal gland	UBERON:0001233	71.62	gold quality
ascending aorta	UBERON:0001496	71.56	gold quality
aorta	UBERON:0000947	70.73	gold quality
mucosa of stomach	UBERON:0001199	70.36	gold quality
popliteal artery	UBERON:0002250	70.19	gold quality
tibial artery	UBERON:0007610	70.17	gold quality
caudate nucleus	UBERON:0001873	69.72	gold quality
duodenum	UBERON:0002114	69.43	gold quality
right frontal lobe	UBERON:0002810	68.27	gold quality
nucleus accumbens	UBERON:0001882	67.61	gold quality
pancreas	UBERON:0001264	67.25	gold quality
epididymis	UBERON:0001301	66.86	gold quality
amygdala	UBERON:0001876	66.72	gold quality
right lobe of thyroid gland	UBERON:0001119	66.66	gold quality
putamen	UBERON:0001874	66.62	gold quality
left adrenal gland	UBERON:0001234	65.54	gold quality
caput epididymis	UBERON:0004358	65.50	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	65.39	gold quality
Brodmann (1909) area 9	UBERON:0013540	65.38	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.78

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NFKB

miRNA regulators (miRDB)

57 targeting CYP4F11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-6086	99.70	65.38	699
HSA-MIR-6766-5P	99.68	67.70	2325

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 10.2% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 7)

• 3-hydroxystearate and 3-hydroxypalmitate are converted to omega-hydroxylated 3-OHDCA precursors in liver; CYP4F11 and, to a lesser extent, CYP4F2 catalyzed omega-hydroxylation of 3-hydroxystearate; CYP4F3b, CYP4F12, and CYP4A11 had negligible activity. (PMID:18065749)
• The CYP4F11 gene is positively regulated by multiple signaling pathways in HaCaT keratinocytes, including retinoid X receptor and JNK signaling pathways. (PMID:19812349)
• Microsomal menaquinone-4 omega-hydroxylation activities correlated with the CYP4F2 V433M genotype but not the CYP4F11 D446N genotype (PMID:24138531)
• results suggest that the metabolism of CYP4F11 substrates may be reduced in individuals carrying the CYP4F11 D315N genetic variant and individuals carrying the common D446N CYP4F11 variant likely exhibit comparable 20-HETE synthesis as individuals expressing wild-type CYP4F11. (PMID:28347661)
• Regulation of cytochrome P450 4F11 expression by liver X receptor alpha. (PMID:33310663)
• A novel gene associated with small bowel bleeding in patients taking low-dose aspirin. (PMID:34059446)
• Deciphering the Role of Fatty Acid-Metabolizing CYP4F11 in Lung Cancer and Its Potential As a Drug Target. (PMID:37973374)

Cross-species orthologs

36 orthologs

Organism	Symbol	Gene ID
danio_rerio	cyp4t8	ENSDARG00000004964
danio_rerio	cyp4f3	ENSDARG00000053530
mus_musculus	Cyp4a31	ENSMUSG00000028712
mus_musculus	Cyp4a32	ENSMUSG00000063929
mus_musculus	Cyp4a10	ENSMUSG00000066072
mus_musculus	Cyp4a30b	ENSMUSG00000084346
rattus_norvegicus	Cyp4a1	ENSRNOG00000009597
rattus_norvegicus	Cyp4a3	ENSRNOG00000066878
drosophila_melanogaster	Cyp4d1	FBGN0005670
drosophila_melanogaster	Cyp4d2	FBGN0011576
drosophila_melanogaster	Cyp4e2	FBGN0014469
drosophila_melanogaster	Cyp4c3	FBGN0015032
drosophila_melanogaster	Cyp4d8	FBGN0015033
drosophila_melanogaster	Cyp4e1	FBGN0015034
drosophila_melanogaster	Cyp4e3	FBGN0015035
drosophila_melanogaster	Cyp4ae1	FBGN0015036
drosophila_melanogaster	Cyp4p1	FBGN0015037
drosophila_melanogaster	Cyp4d14	FBGN0023541
drosophila_melanogaster	Cyp4s3	FBGN0030615
drosophila_melanogaster	Cyp4ac1	FBGN0031693
drosophila_melanogaster	Cyp4ac2	FBGN0031694
drosophila_melanogaster	Cyp4ac3	FBGN0031695
drosophila_melanogaster	Cyp4d21	FBGN0031925
drosophila_melanogaster	Cyp4ad1	FBGN0033292
drosophila_melanogaster	Cyp4p2	FBGN0033395
drosophila_melanogaster	Cyp4p3	FBGN0033397
drosophila_melanogaster	Cyp4aa1	FBGN0034053
drosophila_melanogaster	Cyp4d20	FBGN0035344
drosophila_melanogaster	Cyp312a1	FBGN0036778
caenorhabditis_elegans		WBGENE00007140
caenorhabditis_elegans		WBGENE00009226
caenorhabditis_elegans		WBGENE00010354
caenorhabditis_elegans		WBGENE00013381
caenorhabditis_elegans		WBGENE00016147
caenorhabditis_elegans		WBGENE00021200
caenorhabditis_elegans		WBGENE00021412

Paralogs (12): CYP19A1 (ENSG00000137869), CYP4B1 (ENSG00000142973), CYP4V2 (ENSG00000145476), CYP4A22 (ENSG00000162365), CYP4F22 (ENSG00000171954), CYP4F2 (ENSG00000186115), CYP4Z1 (ENSG00000186160), CYP4F12 (ENSG00000186204), CYP4X1 (ENSG00000186377), CYP4F8 (ENSG00000186526), CYP4F3 (ENSG00000186529), CYP4A11 (ENSG00000187048)

Protein

Protein identifiers

Cytochrome P450 4F11 — Q9HBI6 (reviewed: Q9HBI6)

Alternative names: 3-hydroxy fatty acids omega-hydroxylase CYP4F11, Docosahexaenoic acid omega-hydroxylase, Long-chain fatty acid omega-monooxygenase, Phylloquinone omega-hydroxylase CYP4F11

All UniProt accessions (2): Q9HBI6, F8W978

UniProt curated annotations — full annotation on UniProt →

Function. A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes with high efficiency the oxidation of the terminal carbon (omega-oxidation) of 3-hydroxy fatty acids, such as 3-hydroxyhexadecanoic and 3-hydroxyoctadecanoic acids, likely participating in the biosynthesis of long-chain 3-hydroxydicarboxylic acids. Omega-hydroxylates and inactivates phylloquinone (vitamin K1), and menaquinone-4 (MK-4, a form of vitamin K2), both acting as cofactors in blood coagulation. Metabolizes with low efficiciency fatty acids, including (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) and its oxygenated metabolite 8-hydroxyeicosatetraenoic acid (8-HETE). Catalyzes N- and O-demethylation of drugs such as erythromycin, benzphetamine, ethylmorphine, chlorpromazine, imipramine and verapamil. Catalyzes the oxidation of dialkylresorcinol 2.

Subcellular location. Endoplasmic reticulum membrane. Microsome membrane.

Tissue specificity. Expressed mainly in human liver, followed by kidney, heart, and skeletal muscle.

Post-translational modifications. 4-hydroxynonenal conjugation impairs substrate binding and the long-chain fatty acid omega-monooxygenase activity.

Activity regulation. Inhibition of the long-chain fatty acid omega-monooxygenase activity by 4-hydroxynonenal (4-HNE) conjugation.

Pathway. Lipid metabolism; arachidonate metabolism. Lipid metabolism; oxylipin biosynthesis. Cofactor degradation; phylloquinone degradation. Xenobiotic degradation.

Similarity. Belongs to the cytochrome P450 family.

RefSeq proteins (2): NP_001122404, NP_067010* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001128	Cyt_P450	Family
IPR002401	Cyt_P450_E_grp-I	Family
IPR017972	Cyt_P450_CS	Conserved_site
IPR036396	Cyt_P450_sf	Homologous_superfamily
IPR050196	Cytochrome_P450_Monoox	Family

Pfam: PF00067

Catalyzed reactions (Rhea), 12 shown:

• an organic molecule + reduced [NADPH–hemoprotein reductase] + O2 = an alcohol + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:17149)
• dodecanoate + reduced [NADPH–hemoprotein reductase] + O2 = 12-hydroxydodecanoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:38947)
• 3-hydroxyhexadecanoate + reduced [NADPH–hemoprotein reductase] + O2 = 3,16-dihydroxyhexadecanoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:39731)
• 3-hydroxyoctadecanoate + reduced [NADPH–hemoprotein reductase] + O2 = 3,18-dihydroxyoctadecanoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:39735)
• (5Z,8Z,11Z,14Z)-eicosatetraenoate + reduced [NADPH–hemoprotein reductase] + O2 = 20-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:39755)
• (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + reduced [NADPH–hemoprotein reductase] + O2 = 22-hydroxy-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:40155)
• hexadecanoate + reduced [NADPH–hemoprotein reductase] + O2 = 16-hydroxyhexadecanoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:40199)
• phylloquinone + reduced [NADPH–hemoprotein reductase] + O2 = omega-hydroxyphylloquinone + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:41516)
• menaquinone-4 + reduced [NADPH–hemoprotein reductase] + O2 = omega-hydroxymenaquinone-4 + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:41520)
• (9Z)-octadecenoate + reduced [NADPH–hemoprotein reductase] + O2 = 18-hydroxy-(9Z)-octadecenoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:41728)
• 8-hydroxy-(5Z,9E,11Z,14Z)-eicosatetraenoate + reduced [NADPH–hemoprotein reductase] + O2 = 8,20-dihydroxy-(5Z,9E,11Z,14Z)-eicosatetraenoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:48660)
• 12-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoate + reduced [NADPH–hemoprotein reductase] + O2 = 12,20-dihydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:48664)

UniProt features (15 total): modified residue 6, sequence variant 3, sequence conflict 2, binding site 2, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HBI6-F1	91.91	0.80

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 328 (covalent); 468 (axial binding residue)

Post-translational modifications (6): 45, 260, 261, 347, 354, 451

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-211935	Fatty acids
R-HSA-211958	Miscellaneous substrates
R-HSA-211979	Eicosanoids
R-HSA-2142691	Synthesis of Leukotrienes (LT) and Eoxins (EX)

MSigDB gene sets: 117 (showing top): REACTOME_BIOLOGICAL_OXIDATIONS, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GNF2_GSTM1, GNF2_HPN, GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_KETONE_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_BIOSYNTHETIC_PROCESS, GOBP_WOUND_HEALING, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, GNF2_LCAT, CAIRO_HEPATOBLASTOMA_DN, GOBP_LIPID_METABOLIC_PROCESS, GNF2_HPX, GOBP_ORGANIC_ACID_METABOLIC_PROCESS

GO Biological Process (10): fatty acid metabolic process (GO:0006631), blood coagulation (GO:0007596), arachidonate metabolic process (GO:0019369), oxylipin biosynthetic process (GO:0031408), menaquinone catabolic process (GO:0042361), phylloquinone catabolic process (GO:0042376), vitamin K catabolic process (GO:0042377), omega-hydroxylase P450 pathway (GO:0097267), cytochrome metabolic process (GO:1903604), lipid metabolic process (GO:0006629)

GO Molecular Function (12): monooxygenase activity (GO:0004497), fatty acid binding (GO:0005504), iron ion binding (GO:0005506), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen (GO:0016709), heme binding (GO:0020037), arachidonate omega-hydroxylase activity (GO:0052869), long-chain fatty acid omega-hydroxylase activity (GO:0102033), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712), metal ion binding (GO:0046872)

GO Cellular Component (3): endoplasmic reticulum membrane (GO:0005789), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Cytochrome P450 - arranged by substrate type	3
Arachidonate metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ketone catabolic process	2
oxidoreductase activity	2
monooxygenase activity	2
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	2
lipid metabolic process	1
monocarboxylic acid metabolic process	1
hemostasis	1
wound healing	1
coagulation	1
long-chain fatty acid metabolic process	1
icosanoid metabolic process	1
unsaturated fatty acid metabolic process	1
olefinic compound metabolic process	1
oxylipin metabolic process	1
carboxylic acid biosynthetic process	1
menaquinone metabolic process	1
vitamin K catabolic process	1
fat-soluble vitamin catabolic process	1
vitamin K metabolic process	1
arachidonate metabolic process	1
protein metabolic process	1
primary metabolic process	1
lipid binding	1
monocarboxylic acid binding	1
transition metal ion binding	1
tetrapyrrole binding	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	1
fatty acid omega-hydroxylase activity	1
binding	1
catalytic activity	1
cation binding	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1376 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CYP4F11	CYB5B	O43169	440
CYP4F11	CYP2F1	P24903	433
CYP4F11	PPIG	Q13427	418
CYP4F11	CBR3	O75828	416
CYP4F11	CYP2W1	Q8TAV3	412
CYP4F11	CYP8B1	Q9UNU6	397
CYP4F11	CYB5RL	Q6IPT4	384
CYP4F11	CYB5R4	Q7L1T6	378
CYP4F11	CYB5R1	Q9UHQ9	375
CYP4F11	CYB5R2	Q6BCY4	375
CYP4F11	CYB5R3	P00387	366
CYP4F11	NCKAP5	O14513	361
CYP4F11	CYP26B1	Q9NR63	359
CYP4F11	CYP7B1	O75881	317
CYP4F11	CD109	Q6YHK3	310

IntAct

5 interactions, top by confidence:

A	B	Type	Score
MESD	CYP4F11	psi-mi:“MI:0915”(physical association)	0.560
POT1	CYP4F11	psi-mi:“MI:0915”(physical association)	0.370
CYP4F11	MESD	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (14): CYP4F11 (Affinity Capture-RNA), CYP4F11 (Two-hybrid), CYP4F11 (Proximity Label-MS), CYP4F11 (Proximity Label-MS), CYP4F11 (Proximity Label-MS), CYP4F11 (Proximity Label-MS), CYP4F11 (Proximity Label-MS), CYP4F11 (Proximity Label-MS), CYP4F11 (Proximity Label-MS), CYP4F11 (Proximity Label-MS), CYP4F11 (Proximity Label-MS), CYP4F11 (Affinity Capture-MS), CYP4F11 (Affinity Capture-MS), POT1 (Two-hybrid)

ESM2 similar proteins: A0A087X1C5, E9Q816, O18992, O46658, P00191, P03940, P08686, P10633, P10634, P10635, P11714, P12394, P12938, P12939, P15540, P24456, P24457, P30437, P51589, P51590, P52786, P70085, P78329, Q01361, Q0IIF9, Q29473, Q29488, Q2LA59, Q2LA60, Q2LCM1, Q2XNC8, Q2XNC9, Q4V8D1, Q64403, Q64562, Q64680, Q6GUQ4, Q6VVW9, Q6VVX0, Q7Z449

Diamond homologs: A0A067DT54, A0A067E1K2, A0A0S2II38, A0A140JWM8, A0A1B4XBH8, A0A1W5T1Y6, A0A3Q7HBJ5, A0A517FNB9, A0A517FNC6, A0A5B8ND22, A0A9Y1LLN2, A0AAW1NEA3, A2QTE8, A2RRT9, A2Z212, A9QNE7, B0XZV0, B1NF18, B5BSX1, B6SSW8, B8AJL3, B8AV52, B8QHP1, B8QHP5, B9X287, F1SY66, G3XMC3, I1GQE7, K4CI52, L7T720, L7T8H2, O23051, O35728, O49858, O61387, O81077, O88833, P08682, P0DXH4, P14137

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

126 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	104
Likely benign	8
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1794 predictions. Top by Δscore:

Variant	Effect	Δscore
19:15913910:C:CC	acceptor_gain	1.0000
19:15914300:CTTAC:C	donor_loss	1.0000
19:15914302:TAC:T	donor_loss	1.0000
19:15914303:A:T	donor_loss	1.0000
19:15914664:TGC:T	acceptor_gain	1.0000
19:15914666:CCTG:C	acceptor_loss	1.0000
19:15914667:C:CC	acceptor_gain	1.0000
19:15914667:CTGTG:C	acceptor_loss	1.0000
19:15914668:T:A	acceptor_loss	1.0000
19:15923806:GCCTA:G	donor_loss	1.0000
19:15923807:CCTA:C	donor_loss	1.0000
19:15923808:CTA:C	donor_loss	1.0000
19:15923809:TACC:T	donor_loss	1.0000
19:15923810:A:T	donor_loss	1.0000
19:15923811:C:A	donor_loss	1.0000
19:15924714:C:CA	donor_gain	1.0000
19:15924759:A:AC	donor_gain	1.0000
19:15924759:ACT:A	donor_gain	1.0000
19:15924760:C:CC	donor_gain	1.0000
19:15924760:CT:C	donor_gain	1.0000
19:15924760:CTC:C	donor_gain	1.0000
19:15927210:A:AC	donor_gain	1.0000
19:15927211:C:CC	donor_gain	1.0000
19:15927211:CGTG:C	donor_gain	1.0000
19:15927335:ATCCC:A	acceptor_gain	1.0000
19:15927336:TCCC:T	acceptor_gain	1.0000
19:15927337:CCC:C	acceptor_gain	1.0000
19:15927337:CCCC:C	acceptor_gain	1.0000
19:15927338:CC:C	acceptor_gain	1.0000
19:15927338:CCC:C	acceptor_gain	1.0000

AlphaMissense

3460 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:15914319:G:C	F461L	0.992
19:15914319:G:T	F461L	0.992
19:15914321:A:G	F461L	0.992
19:15927272:G:C	F155L	0.989
19:15927272:G:T	F155L	0.989
19:15927274:A:G	F155L	0.989
19:15914367:G:C	F445L	0.987
19:15914367:G:T	F445L	0.987
19:15914369:A:G	F445L	0.987
19:15914847:G:C	S388R	0.987
19:15914847:G:T	S388R	0.987
19:15914849:T:G	S388R	0.987
19:15927294:C:G	R148P	0.986
19:15927295:G:T	R148S	0.986
19:15913888:G:C	F473L	0.983
19:15913888:G:T	F473L	0.983
19:15913890:A:G	F473L	0.983
19:15913898:C:T	G470E	0.981
19:15924876:A:G	W178R	0.980
19:15924876:A:T	W178R	0.980
19:15913899:C:A	G470W	0.979
19:15922088:C:G	R355P	0.978
19:15913903:G:C	C468W	0.976
19:15914616:A:G	W434R	0.976
19:15914616:A:T	W434R	0.976
19:15927307:A:G	W144R	0.975
19:15927307:A:T	W144R	0.975
19:15922385:C:G	A322P	0.972
19:15913909:T:A	R466S	0.970
19:15913909:T:G	R466S	0.970

dbSNP variants (sampled 300 via entrez): RS1000011714 (19:15926916 G>A,T), RS1000043272 (19:15918557 G>A), RS1000078654 (19:15918314 C>T), RS1000433390 (19:15912182 T>C), RS1000552517 (19:15927161 G>T), RS1000667699 (19:15917184 T>C), RS1001261044 (19:15919029 A>G), RS1001292366 (19:15918706 G>A), RS1001338725 (19:15931296 A>C), RS1001367996 (19:15931518 G>A), RS1001719801 (19:15926799 A>T), RS1001733991 (19:15935704 G>T), RS1001782972 (19:15915009 A>G,T), RS1001915481 (19:15916884 C>T), RS1001979930 (19:15915388 A>C,T)

Disease associations

OMIM: gene MIM:611517 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295949 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs1060467	Dosage	3	warfarin

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1060463	CYP4F11		0.00	0
rs1060467	CYP4F11	3	2.25	1	warfarin
rs8104361	CYP4F11		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — CYP4 family

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.92	IC50	11.9	nM	CHEMBL267865
6.54	IC50	291.3	nM	CHEMBL5272822

PubChem BioAssay actives

2 with measured affinity, of 6 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N’-(4-butyl-2-methylphenyl)-N-hydroxymethanimidamide	1935291: Inhibition of human recombinant CYP4F11 using Luciferin ME EGE as substrate incubated for 30 mins in presence of NADPH by luminescence based assay	ic50	0.0119	uM
ethyl 4-[4-[(hydroxyamino)methylideneamino]phenyl]butanoate	1935291: Inhibition of human recombinant CYP4F11 using Luciferin ME EGE as substrate incubated for 30 mins in presence of NADPH by luminescence based assay	ic50	0.2913	uM

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, increases expression	4
Air Pollutants	increases expression, decreases expression, increases abundance	4
Cyclosporine	increases expression	4
Benzo(a)pyrene	increases expression, increases methylation	3
monomethylarsonous acid	increases expression	2
Silicon Dioxide	decreases expression, increases expression	2
Aflatoxin B1	decreases expression, increases expression	2
Particulate Matter	increases abundance, increases expression	2
aminomethylphosphonic acid (AMPA)	decreases expression	1
Asian ginseng	decreases expression, decreases reaction, affects cotreatment, increases expression	1
propionaldehyde	decreases expression	1
bisphenol A	affects expression	1
lead acetate	increases expression	1
senecionine	increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
2,4,5,2’,4’,5’-hexachlorobiphenyl	increases expression	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	decreases expression	1
periodate-oxidized adenosine	affects expression	1
cupric chloride	increases expression	1
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid	decreases expression	1
avobenzone	increases expression	1
glycidamide	increases expression	1
LG 268	increases expression	1
pyrazolanthrone	decreases reaction, increases expression, decreases expression	1
obeticholic acid	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
NSC 689534	affects binding, increases expression	1
NSC668394	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4256715	ADMET	Drug metabolism in human NCI-H1155 cells assessed as CYP4F11-meidated O-demethylation by measuring half life at 500 nM by LC-MS/MS analysis	Discovery of Cytochrome P450 4F11 Activated Inhibitors of Stearoyl Coenzyme A Desaturase. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.